Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin degludec / insulin aspart) contains the new-generation once ...
Novo Nordisk presented the latest results for its diabetes injectable Tresiba last weekend. These demonstrated significantly better control of blood sugar levels than Sanofi’s Toujeo ...
Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback